Clinical Trial Update: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]

View source ↗

Summary

Clinical trial update indicates CLN-049 is being studied for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome in a Phase 1 study that is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CLN-049 (CLN-049)

Snippet

Sponsor: Cullinan Therapeutics Inc. | Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | Status: RECRUITING